XML 69 R60.htm IDEA: XBRL DOCUMENT v3.25.3
Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details) - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Cash equivalents $ 413 $ 6,954
Related party note receivable 5,725  
Investment in MiNK Therapeutics, Inc. 30,482  
Long-term investments 849 1,006
Total 37,469 7,960
Purchaser Upsize Option   69
Contingent purchase price consideration   318
Total   387
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Cash equivalents 413 6,954
Related party note receivable 0  
Investment in MiNK Therapeutics, Inc. 30,482  
Long-term investments 849 1,006
Total 31,744 7,960
Contingent purchase price consideration   0
Total   0
Significant Other Observable Inputs (Level 2) [Member]    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Cash equivalents 0 0
Related party note receivable 5,725  
Investment in MiNK Therapeutics, Inc. 0  
Long-term investments 0 0
Total 5,725 0
Contingent purchase price consideration   0
Total   0
Significant Unobservable Inputs (Level 3) [Member]    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Cash equivalents 0 0
Related party note receivable 0  
Investment in MiNK Therapeutics, Inc. 0  
Long-term investments 0 0
Total $ 0 0
Purchaser Upsize Option   69
Contingent purchase price consideration   318
Total   $ 387